New hope for Drug-Resistant ovarian cancer: targeted pill vs chemo in phase 3 trial
NCT ID NCT07546500
First seen Apr 24, 2026 · Last updated Apr 29, 2026 · Updated 1 time
Summary
This phase 3 study tests a new targeted drug, azenosertib, against standard chemotherapy in about 420 women with a specific type of ovarian cancer that no longer responds to platinum-based chemo. The cancer must have high levels of a protein called cyclin E1. The goal is to see if azenosertib can slow cancer growth better than chemo. Participants will be randomly assigned to receive either azenosertib pills or one of several chemo drugs chosen by their doctor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.